Prediction of response of EGFR tyrosine kinase inhibtors by plasma DNA
Not Applicable
- Conditions
- ung cancer patients with active EGFR mutations in their tumors
- Registration Number
- JPRN-UMIN000006764
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
No exclusion
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EGFR gene change and heterogeneity by treatment and tumor sites
- Secondary Outcome Measures
Name Time Method